Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections; sodium; chloride; octanoate - indications as at 27 january 2000: hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initital resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initital resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; octanoate; water for injections; sodium - indications as at 27 january 2000 :hypovolaemia/shock: preservation of an adequate cirulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre) or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, aneamia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: octanoate; sodium; water for injections - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium; octanoate - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - 45156 - medicine administration kit, percutaneous, medicated, single-use - the kit consist of a mix2vial (filter transfer device) which is used to facilitate reconstitution by tranfering the diluent from the diluent vial to the freeze-dried product vial. the reconstituted solution is drawn through the mix2vial into a syringe before intravenous injection.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - 45156 - medicine administration kit, percutaneous, medicated, single-use - the procedure pack consists of a vial adapter which is used to facilitate the transfer of the product from the vial into a syringe before subcutaneous injection into the patient.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose; human immunoglobulin a; water for injections - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.